Literature DB >> 12506240

[Chemokine receptor expression of hepatitis B virus-specific CD8+ lymphocyte in chronic B viral infection].

Chun Kyon Lee1, Jeong Hun Suh, Young Suk Cho, Kwang-Hyub Han, Jae Bock Chung, Chae Yoon Chon, Young Myoung Moon.   

Abstract

BACKGROUND/AIMS: The protective role of HBV-specific CD8+ cells is dependent on their ability to efficiently migrate to the infected liver, where they may exert an effector function. The migratory behavior of CD8+ cells is influenced by their expression of different chemokine receptors. This study was intended to analyse the pattern of chemokine receptor expression of HBV specific CD 8+ cells in chronic B viral infection.
METHODS: We analysed the CCR5 and CCR3 profile of HBV-specific CD8+ cells isolated from the blood and liver of patients with different patterns of HBV infection. Purified T cells were stained directly ex vivo, or after antigen-specific stimulation, using HBV peptide-specific HLA tetramers and monoclonal antibodies to CD8, CCR5 and CCR3, with analysis by flow cytometry.
RESULTS: In patients with chronic hepatitis B characterised by low levels of virus (serum HBV DNA <0.5 pg/mL) and minimal liver inflammation, analysis of circulating and intrahepatic CD8+ cells demonstrated that liver infiltrating Tc18-27-specific cells were preferentially CCR5+ (up to 80% of HBV-specific CD8+ cells), in contrast to cells of the same specificity within the circulating compartment (up to 35% of HBV-specific CD8+ cells). Furthermore, CCR3 was expressed by about 10% of Tc18-27+ cells infiltrating the liver, but was absent from circulating cells. Following HBV-specific stimulation in vitro the CCR5 expression of circulating Tc18-27-specific cells was up-regulated, to levels found in liver infiltrating cells, whereas CCR3 expression was unchanged.
CONCLUSIONS: The chemokine receptor profile of HBV-specific CD8+ cells is influenced by the anatomical site of these cells, and the clinical pattern of disease. The ability of circulating HBV-specific CD8+ cells of patients with low replicating virus to upregulate CCR5 suggests that these cells may respond to increases in virus replication by efficiently migrating into the infected liver.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506240

Source DB:  PubMed          Journal:  Taehan Kan Hakhoe Chi        ISSN: 1226-0479


  5 in total

1.  Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.

Authors:  Nirupma TrehanPati; Shyam Kotillil; Syed S Hissar; Shikha Shrivastava; Arshi Khanam; Sukriti Sukriti; Siddartha K Mishra; Shiv Kumar Sarin
Journal:  J Clin Immunol       Date:  2011-02-09       Impact factor: 8.317

2.  Downregulation of CCR5 expression on the peripheral blood CD8+ T cells of southeastern Iranian patients with chronic hepatitis B infection.

Authors:  Behzad Nasiri Ahmadabadi; Gholamhossein Hassanshahi; Hossein Khoramdelazad; Vahid Mirzaei; Seyed Mohammad Ali Sajadi; Masomeh Hajghani; Hassan Khodadadi; Reza Pourali; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

3.  RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population.

Authors:  Jae Youn Cheong; Sung Won Cho; Jeong Young Choi; Jung A Lee; Min Ho Kim; Jong Eun Lee; Ki Baik Hahm; Jin Hong Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

4.  CCR5 on the NK Cells and its Ligand (RANTES) Expressions are Disrupted in South-Eastern Iranian Patients With Chronic Hepatitis B Infection.

Authors:  Vahid Mirzaee; Jahanbano Shahriari; Masomeh Hajghani
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

Review 5.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.